Spoken Alpha
AEON Biopharma, Inc.
AEON Biopharma develops ABP-450, a botulinum toxin complex, as a biosimilar to Botox® for therapeutic medical conditions including chronic migraine, cervical dystonia, and spasticity.
AEON Biopharma, Inc is a Healthcare company operating in Biotechnology with a $12.3M market cap.
AEON beat consensus EPS by 0.9% in Q2 FY2026, reported Aug 11, 2026.
Behavioral analysis
Disclosures
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add AEON, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AEON.
$ curl https://api.spokenalpha.com/v1/companies/AEONFAQ
Spoken Alpha indexes AEON's earnings call transcripts at https://spokenalpha.com/companies/AEON. Each call links to attributed speakers and parsed analyst Q&A.
AEON Biopharma, Inc. (AEON) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | $-0.02 | $-0.33 | +93.9% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-0.25 | $-0.44 | +43.2% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-3.72 | $-0.20 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-0.39 | $-0.43 | +9.3% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.60 | $-0.35 | -71.4% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-13 | $2.28 | — | — | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-23 | $3.47 | — | — | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-11.52 | $-11.52 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $5.34 | $-13.68 | +100.0% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-0.28 | $-0.31 | +9.7% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-28 | $-51.12 | $-28.80 | -77.5% | — | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $82.80 | $-38.16 | +100.0% | — | — | — | EODHD |
| Q2 FY2023 | 2023-08-29 | $-31.88 | — | — | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-30 | $-1.40 | — | — | $0 | — | — | EODHD |
| Q4 FY2022 | 2022-12-30 | $0.19 | — | — | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-09-29 | $3.43 | — | — | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-06-29 | $3.90 | — | — | — | — | — | EODHD |
| Q1 FY2022 | 2022-03-30 | $5.79 | — | — | — | — | — | EODHD |
| Q4 FY2021 | 2021-12-30 | $0.52 | — | — | — | — | — | EODHD |
| Q3 FY2021 | 2021-10-03 | $-1.66 | $0.00 | — | — | — | — | EODHD |
Source: EODHD. AEON reported actuals as published; sparse fields render as —.